Surrozen (SRZN) Non-Current Assets (2020 - 2026)
Surrozen (SRZN) recorded quarterly Non-Current Assets of $6.8 million in Q1 2026, down 5.68% quarter-over-quarter from $7.2 million in Q4 2025, and down 23.34% on a YoY basis from $8.8 million in Q1 2025.
Surrozen (SRZN) Non-Current Assets (2020 - 2026) Analysis & Trends
Surrozen's Non-Current Assets history runs 7 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 23.34% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $30.6 million (up 24.8% YoY), while the FY2025 annual figure was $7.2 million, down 24.83% from the prior year.
- Non-Current Assets was $6.8 million for Q1 2026 at Surrozen, down from $7.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $22.0 million in Q1 2022 to a low of $2.7 million in Q3 2024.
- Historically, Non-Current Assets has averaged $7.8 million across 5 years, with a median of $7.2 million in 2025.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 89.89% in 2022, then soared 201.84% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $8.1 million in 2022, then plunged by 39.14% to $4.9 million in 2023, then jumped by 92.7% to $9.5 million in 2024, then retreated by 24.83% to $7.2 million in 2025, then dropped by 5.68% to $6.8 million in 2026.
- The last three Non-Current Assets figures came in at $6.8 million (Q1 2026), $7.2 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 39.71 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 6.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.76 Mn |
| Dec 31, 2025 | 7.17 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 8.46 Mn |
| Mar 31, 2025 | 8.82 Mn |
| Dec 31, 2024 | 9.54 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 4.70 Mn |
| Dec 31, 2023 | 4.95 Mn |
| Sep 30, 2023 | 5.62 Mn |
| Jun 30, 2023 | 6.42 Mn |
| Mar 31, 2023 | 7.17 Mn |
| Dec 31, 2022 | 8.13 Mn |
| Sep 30, 2022 | 8.72 Mn |
| Jun 30, 2022 | 9.31 Mn |
| Mar 31, 2022 | 21.98 Mn |
| Dec 31, 2021 | 31.99 Mn |
| Sep 30, 2021 | 36.63 Mn |
| Jun 30, 2021 | 92.03 Mn |